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Sweet dysgeusia, a rare taste disorder, may be encountered in severe anti-acetylcholine receptor antibody
(AChRAb)-myasthenia gravis (MG). A 42 year-old man reported progressive loss of sweet taste evolving for almost
10 weeks, revealing an AChRAb-positive MG with thymoma. Improvement of sweet perception paralleled reduction of
the MG composite score during the 15 months follow up period, with immunosuppressive and surgical treatments.
We suggest that sweet dysgeusia is a non-motor manifestation of MG that may result from a thymoma-dependent
autoimmune mechanism targeting gustducin-positive G-protein-coupled taste receptor cells, in line with recent data
from MRL/MpJ-Faslpr/ (MRL/lpr) transgenic mice with autoimmune disease.
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Myasthenia Gravis (MG) is an autoimmune disorder char-
acterized by fluctuating muscle weakness and ocular or
bulbar signs [1]. Non-motor symptoms may however de-
velop, including taste disorders, which concern 5% of
cases. In these patients, thymoma is common and associ-
ated with severe MG [2,3]. Here, we describe the kinetics
of sweet taste loss related to a mild anti-acetylcholine re-
ceptor antibody (AChRAb)-positive MG and its recovery
along with disappearance of myasthenic symptoms under
treatment. In light of the literature, this case further un-
derlines the particular association of selective sweet taste
disorder with thymoma-associated MG, our hypothesis
being the coexistence of an autoantibody selectively target-
ing G-protein-coupled receptor cells (GPCRs).Case report
A 42 year-old healthy man complained of progressive and
prominent loss of sweet taste with mild salt taste impair-
ment evolving over ten weeks. On examination, olfactory
and trigeminal functions were normal. Taste function was
absent for sweet, impaired for bitter, uncertain for sour
and normal for salt (Figure 1a). Brain MRI and CSF ana-
lysis were normal. The usual causes of taste disturbance* Correspondence: thierry.kuntzer@chuv.ch
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unless otherwise stated.were excluded [4], including normal serum zinc levels. Six
weeks after taste disorders onset, the patient reported fluc-
tuating diplopia worsening in the evenings, correlated with
variable gaze abnormalities on consecutive evaluations, no
muscle weakness, but general fatigue. Therefore, investiga-
tions were undertaken, displaying a 20% surface decre-
ment upon 3-Hz repetitive nerve stimulation of the
accessory nerve to upper trapezius muscle, and elevated
serum AChRAb level (114 pmol/ml, normal < 0.2), con-
firming a MGFA class I MG [5]. Pyridostigmine improved
most of the symptoms including dysgeusia. A large infil-
trating thymoma (80% B2 and 20% B3 in WHO classifica-
tion, pT2 N0 Mx and modified-Masaoka-Conga type IIa)
was discovered in the chest CT-scan, and surgically re-
moved with consecutive myasthenic crisis requiring 2 weeks
ICU care. Under immunosuppressive therapy (azathioprine
shifted to mycophenolate mofetil due to liver toxicity) asso-
ciated to prednisone and pyridostigmine, the patient grad-
ually recovered. Fifteen months clinical follow up showed
MG composite score improvement from 14 to 3/41 and a
sweet dysgeusia numeric scale progress (dysgeusia subject-
ive scale, DSS:0; lack of perception to 10; normal percep-
tion) from 0 to 6/10 (Figure 1b). Psychophysical olfactory
and gustatory testings [6] were then normal. The patient
enjoyed sweet foods again and could return to work.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Taste evaluation and variation of the dysgeusia according to treatment. a (top panel). Taste evaluation performed 3 months after
loss of sweet taste, conducted as shown, on the left and right of the anterior part of the tongue and globally on the posterior part. Perception of
sweet was overall impaired and salt perception was normal. Bitter was only perceived at the posterior part, while sour test results changed from
one evaluation to another (*). N: normal perception; D: diminished; A: abolished. b (bottom panel). Variations of the dysgeusia subjective score
(DSS, light gray squares, right ordinates) according to MG composite score (MGCS, black squares, left ordinates) during the 16 months follow-up
period. MG score improved in parallel with recovery in sweet perception for one year, then both scores stabilize, with an almost normal MGCS
and a 60% of normal sweet perception. The high MGCS at month 5 corresponds to the MG crisis after thymoma removal.
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Taste impairment (mainly sweet dysgeusia) is rare in MG
[2,3] and remains a very unusual presentation of taste dis-
orders [7]. Within the taste buds, GPCRs are responsible
for sweet, bitter and umami taste detection whereas salty
and sour transduction is GPCR-independent [8]. The se-
lective sweet taste deficit in MG suggests therefore dys-
function in GPCR-containing receptor cells. Although
most of GPCRs are narrowly tuned to a specific taste mo-
dality, some correspond to more than one taste [9], pos-
sibly explaining additional taste perception deficits in MG.
Sweet dysgeusia always coexists with thymoma in MG,
suggesting a paraneoplastic phenomenon corroborated by
its repeated description as first sign of lung cancer [10].
However, sweet taste disappears in MG whereas it is dis-
torted in lung cancer [10]. In our patient, dysgeusia coex-
isted with mild myasthenic symptoms and recovered in
parallel with them under treatment [2]. Moreover, in all
reported MG-associated dysgeusia cases (usually severe),
both AChRAb and thymoma were present, and dysgeusia
evolved in parallel with AChRAb titers [11]. We concludethat dysgeusia shared a common pathological background
with MG [3].
MG has a clear autoimmune substrate [1] with a pri-
mary pathogenic role for the thymus. Both experimental
autoimmune MG animal model and analysis of circulating
antibodies in MG patients indicate a T-cells dependent
mechanism [1,12] originating from the thymoma [3].
Transgenic MRL/lpr mice, used as an experimental model
for autoimmune diseases, have immunopathologic fea-
tures partially similar to those described in MG. Interest-
ingly, they were found with increased T-cell infiltration
and selectively decreased α-gustducin positive taste recep-
tor cells in taste buds. Alpha-gustducin, a G-protein sub-
unit co-expressed with almost all T1 and T2 receptors in
GPCR, is responsible for sweet, bitter and umami percep-
tion [8]. As expected, MRL/lpr transgenic mice displayed
diminished gustatory nerve response to bitter and sweet
compounds, and reduced behavioral response to bitter,
sweet and umami substances, while their salt and sour
taste cells characteristics and behavior did not differ from
control animals [12]. All together, these observations
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(sweet) dysgeusia. Furthermore, various antibodies associ-
ated with thymic abnormalities in MG are reported without
any clearly defined contribution to the pathology and the
severity of the disease [1,13]. We hypothesize that one of
them could target α-gustducin positive receptor cells, dis-
turb taste signaling and that way elicit dysgeusia in MG [2].
Our case and recent reports indicate thymoma-
associated MG with AChRAb as a plausible etiology of
sweet taste loss, possibly due of an autoimmune mechan-
ism targeting GPCRs taste cells expressing α-gustducin as
the underlying mechanism. We strongly emphasize that
unexplained selective sweet taste alteration, associated
with possibly overlooked mild MG, as in our patient, de-
serves thorough workup with a high degree of suspicion
for a paraneoplastic origin.
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